Aio peptides ApoA-I mimetic peptides are synthetic molecules designed to replicate the beneficial effects of apolipoprotein A-I (apoA-I), the primary protein component of high-density lipoprotein (HDL). These peptides hold significant promise as therapeutic agents, particularly for cardiovascular diseases, due to their ability to mimic apoA-I's antiatherogenic propertiesApolipoprotein Mimetic Peptides: Potential New Therapies .... Research indicates that apoA-I mimetic peptides can inhibit atherosclerosis by promoting reverse cholesterol transport, reducing lipoprotein oxidation, and exerting anti-inflammatory effects.
Apolipoprotein A-I (apoA-I) plays a crucial role in lipid metabolism and cardiovascular health. It is the main protein in HDL particles, often referred to as "good cholesterol," and is instrumental in removing excess cholesterol from peripheral tissues and transporting it back to the liver for excretion.作者：LL Hsu·2009—These preclinical data provide a mechanistic basis for the effects ofApoA-Iin sickle cell disease and suggest thatApoA-Imimetics deserve further study as a potential therapy for sickle cell disease. However, it is unknown whether acute administration of anApoA-I mimetichas any efficacy for sickle ... This process, known as reverse cholesterol transport, is a key defense against the buildup of atherosclerotic plaques in arteries.An apoA-I mimetic peptide increases LCAT activity in mice ...
ApoA-I mimetic peptides are short peptide sequences engineered to emulate the amphipathic helical structures within apoA-I that are responsible for its functional activities. By doing so, these peptides can activate enzymes like lecithin:cholesterol acyltransferase (LCAT), which is involved in cholesterol esterification, and facilitate cholesterol efflux from cells作者：GS Getz·2011·被引用次数：84—TheapoA-I mimetic peptideis a much simpler reagent for therapeutic purposes than HDL or apoA-I. It too may promote reverse cholesterol transport (not yet well.. This functional mimicry makes them attractive candidates for therapeutic development, offering a potentially simpler and more controllable alternative to administering HDL or apoA-I itself.
The primary focus for apoA-I mimetic peptides has been the treatment and prevention of cardiovascular diseases, particularly atherosclerosis. Studies have demonstrated their efficacy in various models:
* Antiatherogenic Effects: Peptides like the well-studied 4F series (both L-4F and D-4F) have shown significant ability to inhibit atherosclerosis progression in preclinical studiesA novel apoA‐I mimetic peptide suppresses .... They achieve this by increasing the formation of pre-beta HDL, enhancing cholesterol efflux, and reducing the oxidation of lipoproteins, a process that contributes to plaque formation.
* Anti-inflammatory Properties: Beyond lipid management, apoA-I mimetic peptides exhibit potent anti-inflammatory effects. This is crucial because inflammation plays a significant role in the development and progression of atherosclerosis. These peptides can bind oxidized lipids, thereby mitigating inflammatory responses within the arterial wall.
* Vascular Protection and Angiogenesis: Emerging research suggests that apoA-I mimetic peptides can confer robust vascular protection and may promote physiological, hypoxia-mediated angiogenesis作者：M Ditiatkovski·2017·被引用次数：31—Apolipoprotein AI (apoA-I) mimetic peptideshave antiatherogenic properties of high-density lipoproteinin vitro and have been shown to inhibit atherosclerosis .... This could be beneficial in conditions where blood flow is compromisedApoA-I Mimetic Peptides: A Review of the Present Status.
While cardiovascular applications remain central, research is exploring the potential of apoA-I mimetic peptides in other disease areas:
* Cancer Therapy: Some apoA-I mimetic peptides have shown the ability to reduce the viability and proliferation of certain cancer cells, including platinum-resistant ovarian cancer cells作者：S Gou·2020·被引用次数：19—AAMPs are short peptides thatcan mimic the physiological effects of apoA-I, including the suppression of atherosclerosis by reversely transporting peripheral .... This suggests a potential role in adjunctive cancer therapyApoA-I Mimetic Peptides as Anti-Inflammatory Agents.
* Neurological Conditions: Peptide 5A, an apoA-I mimetic peptide, has demonstrated a remarkable enhancement of remyelination, both ex vivo and in vivo. This finding opens avenues for its investigation in treating demyelinating diseases.Apolipoprotein AI Mimetic Peptides Prevent Atherosclerosis ...
* Inflammatory Bowel Disease: The 5A peptide has also proven effective in ameliorating murine colitis by preventing intestinal monocyte infiltration and activation, highlighting its broader anti-inflammatory capabilities.
* Sickle Cell Disease: Preclinical data suggests that apoA-I mimetics may offer a mechanistic basis for therapeutic intervention in sickle cell disease, warranting further investigation.
The design of apoA-I mimetic peptides involves creating sequences that effectively mimic the amphipathic helical nature of apoA-I. This can include peptides synthesized from all D-amino acids (like D-4F) or all L-amino acids (like L-4F), offering different pharmacokinetic and stability profiles.Systematic evaluation of the effect of different ... Researchers have developed various designs, some containing a specific number of amino acids, such as the 18-amino acid peptide initially proposed, while others, like the Fukuoka Apo A-I Mimetic Peptide (FAMP), are more complex, consisting of 24 amino acids without phospholipids.
Clinical trials have begun to assess the safety and efficacy of these peptides. For instance, early reports on oral administration of D-4F in humans indicated good tolerability and rapid absorption.The 5A apolipoprotein A‐I (apoA‐I) mimetic peptide ... The development of these peptides represents a significant advancement in peptide-based therapeutics, aiming to harness the multifaceted benefits of apoA-I in a more targeted and potentially more accessible manner作者：M Ditiatkovski·2013·被引用次数：38—Apolipoprotein A-I (apoA-I) mimetic peptidesare considered a promising novel therapeutic approach to prevent and/or treat atherosclerosis. An apoA-I mimetic ....
ApoA-I mimetic peptides represent a compelling class of therapeutic agents with demonstrated potential to combat cardiovascular diseases by mimicking the protective functions of apolipoprotein A-I.作者：M Navab·2005·被引用次数：312—The main protein of high-density lipoprotein (HDL), apolipoprotein A-I (apoA-I), contains 243 amino acids. The ability ofapoA-Ito remove phospholipids and ... Their ability to promote reverse cholesterol transport, reduce inflammation, and enhance vascular health makes them highly attractive for drug development. Furthermore, emerging research into their applications in cancer, neurological disorders, and inflammatory conditions underscores their broad therapeutic promise. As research and clinical trials continue, apoA-I mimetic peptides are poised to become important tools in addressing a range of challenging health issues.
Join the newsletter to receive news, updates, new products and freebies in your inbox.